ExTRANODAL NK/T cell lymphoma, nasal type: a rare diagnosis with common nasal presentation

Siti Sarah Mohd Ramli 1, Salina Husain 1, Yin Ping Wong 2

SUMMARY
A 39-year-old man presented with bilateral nasal obstruction for 4 months and associated with hyposmia and foul-smelling nasal discharge. Nasal endoscopy showed irregular mucosa of the nasal cavity with easily bleeding. Nasal biopsy reported as extranodal Natural Killer/T cell lymphoma, nasal type. In-situ hybridisation for Epstein-Barr encoding region was positive. He was treated with six cycles of gemcitabine, oxaliplatin and L-asparaginase and peripheral blood stem cell transplant. After the treatment, he was asymptomatic until 9 months where he had splenic abscess and undergone splenectomy. He was asymptomatic of the disease for 2 years.

BACKGROUND
Extranodal Natural Killer/T cell lymphoma, nasal type (ENKTCL,NT) nasal type is an aggressive, rare subtype of non-Hodgkin’s lymphoma (NHL) which 70%–80% of ENKTCL,NT occurs at upper aerodigestive tract.1–3 It constitutes of only 3%–12% cases of NHL.4–7 The prevalence of ENKTCL,NT is higher in Asia, where 8% in Hong Kong, as compared with the Western countries where it only accounts for 2% of NHL in Lyon.8–9 All of ENKTCL,NT was accompanied with infection of Epstein-Barr virus (EBV)10 11 and EBV DNA load is a surrogate marker for patient’s prognosis.12

CASE PRESENTATION
A previously healthy 39-year-old man presented with progressive bilateral nasal obstruction for 4 months. It was associated with foul smelling discharge, epistaxis and hyposmia. He was an active smoker but there was no history of malignancy in his family. In clinical setting, both nasal cavity were obstructed with oedematous nasal mucosa. There was no cervical node palpable. Nasal endoscopy under anaesthesia revealed irregular, oedematous and easily bled septal mucosa obstructing the nasal passage bilaterally (figure 1). There was no mass or pus discharge seen at the osteomeatal complex.

INVESTIGATIONS
Full blood picture showed leucoerythroblastic picture with occasional myelocytes and nucleated red blood cells(NRBC). There was severe normochromic, normocytic anaemia. Otherwise, the red cells showed no abnormalities and white blood cells were within normal range. There was no abnormal lymphoid cells seen.

Computed tomography scan (CT scan) of the paranasal sinuses revealed an enhancing soft tissue density lesion occupying right nasal cavity with deviation of nasal septum to the left (figure 2). There were remodelling and thinning of adjacent bones. Ethmoid sinuses, sphenoid and frontoethmoidal recesses were obliterated. There was no significant neck node seen.

Histopathological examination of the lesion (figure 3) exhibited diffuse sheets of malignant lymphoid cells in a mixed inflammatory background. The malignant lymphoid cells displayed enlarged, pleomorphic hyperchromatic nuclei with inconspicuous nucleoli and moderate cytoplasm. Frequent mitosis was observed. Angio-centricity and angiodestruction were focally noted, leading to zonal necrosis. Immunohistochemical studies (figure 4) reported the malignant lymphoid cells were positive for CD3, CD2, CD5, CD7, CD8 and TIA-1. The proliferation index (Ki 67) was about 30%. Epstein-Barr encoding region (EBER) was tested positive by in situ hybridisation confirming the diagnosis of ENKTCL,NT.

Bone marrow biopsy showed tumour cells infiltration forming focal aggregates at central area. The tumour cells were moderate to large in size, irregular nuclear outline, vesicular chromatin with prominent nucleoli and abundant cytoplasm. Immunohistochemical staining showed the abnormal lymphoid cells were positive to CD2, CD3, CD5, CD7, TIA-1 and in situ hybridisation for EBER. It was negative for CD20 and CD56. This was consistent with infiltration by NK/T cell lymphoma.

Positron emission tomography-computed tomography (PET-CT) was done prior to treatment for staging of ENKTCL, NT and disease was only presented at paranasal sinuses, nasopharynx and oropharynx.

DIFFERENTIAL DIAGNOSIS
Due to the history and examination during the first encounter, the provisional diagnosis was bilateral nasal polyposis with consideration of inverted papilloma.

Post examination of the nose under anaesthesia, the diagnosis was sinonasal granulomatous disease with query of Wegener granulomatosis. ENKTCL, NT was lower on the list. Histopathological examination confirmed of the diagnosis of ENKTCL, NT, stage IV disease based on Ann Arbor staging system as there was bone marrow filtration.

TREATMENT
He was treated with six cycles of a combination of gemcitabine, oxaliplatin and L-asparaginase...
(GELOX) with additional intravenous gemcitabine. Peripheral blood stem cell transplantation (PBSCT) showed complete engraftment within 3 weeks.

OUTCOME AND FOLLOW-UP
PET-CT study 6 months post-PBSCT showed complete metabolic response. There was no active disease at primary site (nasal cavities). However, he developed prolonged fever and lethargy with pancytopenia 9 months post treatment. Blood culture and sensitivity showed no growth. Cytogenetic analysis of the G-banded chromosomes from cultured bone marrow showed a male chromosome complement with no evidence of a clonal abnormality. CT scan showed hepatosplenomegaly with multiple hypodensities consistent with splenic abscess. He underwent splenectomy. At 18 months follow-up, the patient was asymptomatic of nasal symptoms and nasal endoscopy revealed normal nasal and septal mucosa.

DISCUSSION
WHO recognises three major categories of extranodal ENKTCL; ENKTCL,NT, which started with nasal symptoms; enteropathy-type, which patient presented with coeliac disease; and subcutaneous panniculitis like, which patient presented with multiple subcutaneous nodules. ENKTCL,NT is an aggressive type of NHL that accounted around 3%–12% of all cases of NHL, ranging highest in Asian and lower percentage of all NHL in Western countries. In Malaysia, the difference of disease prevalence between ethnicity was observed, where Chinese was found to be more predisposed to EBV-associated tumour such as ENKTCL,NT compared with non-Chinese group which was half of the risk. It affects male patients more than female.

Initially, majority of ENKTCL, NT patients presented with general nasal symptoms such as nasal obstruction, epistaxis, nasal discharge and reduced smell sensation, which might be mistaken for bacterial or fungal rhinosinusitis or in more progressive disease, patients might be suspected for more common condition such as Wegener granulomatosis, inverted papilloma, and in some region, nasal tuberculosis. As the disease progressed, most patient presented with facial oedema, mid face necrosis and destruction of adjacent structures occur, which caused collapsed of the lateral nasal wall cavity and oronasal fistula. In locally advanced cases, there would be involvement of orbits, hard palate, oropharynx and larynx. Multiple biopsies may be required as there would be abundant of necrotic tissues. Delay of diagnosis may lead to dissemination of disease to lungs, gastrointestinal tract, testicles, kidneys, pancreas, central nervous system and skin. ENKTCL,NT might spread to marrow and presented with leukaemic phase. Our patient had bone marrow infiltration with severe normochromic normocytic anaemia without pancytopenia.

Studies in Asia found that ENKTCL,NT patients was positive for in situ hybridisation of EEBER. The presence of EBV was deemed to be required for diagnosis of ENKTCL,NT. Studies showed EBV has two subtypes; A and B, where subtype A was found common in many Asian ENKTCL,NT cases and might be an important etiopathogenetic component for Asian with ENKTCL,NT. High circulation EBV-DNA pretreatment carried poor prognosis for ENKTCL,NT patients.

CD2, CD3, CD7 and CD56 represents phenotypic markers for natural killer(NK) normal cells. In a study using tissue
microarray, ENKTCL,NT were found positive for CD3, CD4, CD, CD7, CD45, CD30, CD56, TIA-1, granzyme B, Oct2, perforin and IRF4/MUM1, where TIA-1 was demonstrated in all of the 22 cases studied. In addition of positive EBER in situ hybridisation, TIA-1, CD2, CD3, CD5 and CD7 were positive in our patient, confirming the diagnosis of ENKTCL,NT. Although CD56 was negative, it did not rule out the diagnosis of ENKTCL, NT.

For ENKTCL, NT staging, Ann Arbour staging is generally used, however, some study suggested for tumour, node, metastasis (TNM) staging based on American Joint Committee of Cancer (AJCC) staging for nasopharyngeal carcinoma, or para-nasal sinuses and nasal cavity cancers. In our patient, he was diagnosed as stage IV ENKTCL, NT as he had bone marrow infiltration. Choices of treatment might be based on stages of the presenting ENKTCL, NT. Studies recommended chemotherapy with adjuvant radiotherapy as the gold standard treatment of ENKTCL, NT. Choices of chemotherapy may be varied. Recent study showed better outcome in patients receiving L-asparaginase-based regimens such as a combination of GELOX regimen, with overall 5-year overall survival (OS) rate (OS) of 85%, or a combination of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE regimen), with 1-year OS of 55% or a combination of combined asparaginase, methotrexate and dexamethasone (AspaMetDex), showed 1-year OS of 61%, as compared with a combination of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone-based regimen, with 5-year OS of only 48%. There was also a study for concomitant chemoradiotherapy using a combination of dexamethasone, etoposide, ifosfamide and carboplatin regimen for localised ENKTCL, with the 5-year OS was 70%.

In early-stage ENKTCL,NT, up to 85% of the patients may have complete remission with the current treatment based on chemotherapy regimen. However, advanced ENKTCL,NT (stage III/IV) had a very poor prognosis. Despite of the challenge, a retrospective analysis showed favourable outcome for advanced ENKTCL,NT patients who received high-dose chemotherapy and peripheral blood stem cell transplant (PBSCT), with a 5-year OS rate of 50%. Further study on haematopoietic stem cells transplantation currently expanded for the future use of lymphoma treatment.

Our patient was treated with GELOX regimen chemotherapy with additional intravenous gemcitabine and later with PBSCT. The result showed complete remission of the disease at an 18 months follow-up.

Acknowledgements The authors acknowledge with thanks the contribution of Farah Dayana Zahedi, Associate Professor of Rhinology, Specialist of Otorhinolaryngology; Aneza Khairiyah Wan Hamizan, Associate Professor of Rhinology, Specialist of Otorhinolaryngology; and Ruhana Amirah binti Abdul Halim, Postgraduate student of Pathology Medicine, all three at Universiti Kebangsaan Malaysia for contributing information of the patient and interpreting the data in the case report.

Contributors The authors declare that no conflicts of interest exist in relation to the published work/describe potential conflicts of interest below*. (*delete as applicable) Name and surname Signature Date (1) SSMR, 5 May 2021. (2) SH, 5 May 2021. (3) YPW, 5 May 2021 Permission from the head (heads) of the institution to submit the work for publication (not applicable to manuscripts submitted by independent research fellows): (1) SH, Head of Department, Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM).

Funding This study was funded by Universiti Kebangsaan Malaysia 862406.

Competing interests None declared.

Patient consent for publication Parental/guardian consent obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Siti Sarah Mohd Ramli http://orcid.org/0000-0001-9566-3007 Salina Husain http://orcid.org/0000-0001-7683-2143 Yin Ping Wong http://orcid.org/0000-0003-4897-9927
REFERENCES